A Phase 1, Open-label Study Evaluating the Safety and Tolerability of Escalating Doses of DLYE5953A in Patients with Refractory Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Jul 2020

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs RG 7841 (Primary)
Indications Advanced breast cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Sponsors Genentech

12 Jul 2020 Results evaluating safety, pharmacokinetics, immunogenicity, potential biomarkers, and anti tumor activity of DLYE5953A in patients with solid tumors, published in the Clinical Cancer Research
04 Dec 2017 Status changed from active, no longer recruiting to completed.
11 Oct 2016 Results (n=57, as of 31st December 2015) presented at the 41st European Society for Medical Oncology Congress

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com